Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

Women's Hospital School Of Medicine Zhejiang University

Status and phase: Enrolling; Phase 2

Conditions: Immunochemotherapy; Cervical Cancer

Treatments: Drug: Camrelizumab combined with chemotherapy

Study type: Interventional

Funder types: Other

Identifiers

NCT07167160

IRB-20250023

Details and patient eligibility

About

Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.

Enrollment: 59 estimated patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
2. Positive PD-L1 expression;
3. ECOG score ≤1

Exclusion criteria

1. Positive parametrium or surgical margin;
2. Incomplete radical surgery;
3. Residual target lesions;
4. Active autoimmune disease or autoimmune disease requiring systemic treatment;
5. Previous treatment with immune checkpoint inhibitors.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

59 participants in 1 patient group

chemotherapy group

Experimental group

Treatment:

Drug: Camrelizumab combined with chemotherapy